![Cancers | Free Full-Text | Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry Cancers | Free Full-Text | Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry](https://www.mdpi.com/cancers/cancers-12-02911/article_deploy/html/images/cancers-12-02911-g001.png)
Cancers | Free Full-Text | Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
![Cancers | Free Full-Text | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Cancers | Free Full-Text | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390](https://www.mdpi.com/cancers/cancers-12-00808/article_deploy/html/images/cancers-12-00808-g001.png)
Cancers | Free Full-Text | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390
![Markéta POSPÍŠKOVÁ | medical doctor | T. Bati Regional Hospital, Zlin | Department of Medical Oncology | Research profile Markéta POSPÍŠKOVÁ | medical doctor | T. Bati Regional Hospital, Zlin | Department of Medical Oncology | Research profile](https://i1.rgstatic.net/ii/profile.image/841338559922176-1577602152160_Q512/Marketa-Pospiskova.jpg)
Markéta POSPÍŠKOVÁ | medical doctor | T. Bati Regional Hospital, Zlin | Department of Medical Oncology | Research profile
Seznam onkologických pracovišť a onkologů zajišťujících prevence pro osoby (i zdravé) s dědičným rizikem nádorů
![Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/03ea64b3-8bc1-4956-a1fb-634144317b3c/gr1.jpg)